Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Loss of Function Clear all
Recruiting Not applicable Interventional

A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program

NCT05748158
View directory record Official record
Conditions
Obesity
Interventions
Weight loss
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 59 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

NCT01598987
View directory record Official record
Conditions
Renal Function, Liver Transplant
Interventions
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 21, 2026, 2:36 PM EDT
Not listed Not applicable Interventional

Behavioral Weight Loss and Exercise After Treatment (BEAT)

NCT02052115
View directory record Official record
Conditions
Breast Cancer
Interventions
12 month exercise and weight loss intervention
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
21 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 2 Interventional Results available

FX-322 in Adults With Stable Sensorineural Hearing Loss

NCT04120116
View directory record Official record
Conditions
Sensorineural Hearing Loss, Noise Induced Hearing Loss, Sudden Sensorineural Hearing Loss
Interventions
FX-322 (One Dose), FX-322 (Two Doses), FX-322 (Four Doses), Placebo
Drug
Lead sponsor
Frequency Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Fresno, California • Torrance, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 21, 2026, 2:36 PM EDT
Withdrawn Phase 3 Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676
View directory record Official record
Conditions
Platinum Sensitive Relapsed Ovarian Cancer
Interventions
OLAPARIB, PLACEBO
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 96 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Including Almonds in a Weight Loss Trial

NCT02360787
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Energy restriction, Almonds (15% kcal/day)
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 21, 2026, 2:36 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Auditory-Cognitive Training to Optimize Outcomes for Older CI Users

NCT05176561
View directory record Official record
Conditions
Hearing Loss, Deafness
Interventions
Auditory-Cognitive Training, Non-auditory Cognitive Training
Behavioral
Lead sponsor
Gallaudet University
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Intervention and Varying Physical Activity in Seniors

NCT01893684
View directory record Official record
Conditions
Obesity
Interventions
Exercise, Higher Protein Diet, Conventional Carbohydrate Diet
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
65 Years to 80 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Not applicable Interventional

Metabolism of Low Carbohydrate and Ketogenic Diet

NCT05071287
View directory record Official record
Conditions
Diabetic Kidney Disease, Cognitive Function, Weight Loss, Diabetic Control, Type2 Diabetes
Interventions
mHealth + low-fat diet, mHealth + low-carb/ketogenic diet
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 21, 2026, 2:36 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Bariatric Endoscopic Antral Myotomy (BEAM) as a Treatment for Obesity

NCT05713071
View directory record Official record
Conditions
Obesity, Weight Loss, Delayed Gastric Emptying Following Procedure, Obesity, Mild, Obesity, Morbid, Obesity; Excess Calories
Interventions
Bariatric Endoscopic Antral Myotomy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

NCT07030257
View directory record Official record
Conditions
Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
Interventions
CP-383
Drug
Lead sponsor
Tasca Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Outcomes After Participating in Exercise (HOPE)

NCT03430115
View directory record Official record
Conditions
Weight Loss, Obesity, Aging
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 21, 2026, 2:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The WISE (Weightloss Intervention Surgical Effects) Brain Study

NCT02137070
View directory record Official record
Conditions
Diabetes, Weightloss
Interventions
Bariatric Surgery Candidates, Non surgical/Community volunteers
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
20 Years to 75 Years
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 21, 2026, 2:36 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Recruiting No phase listed Observational

Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome

NCT05528744
View directory record Official record
Conditions
Genetic Disease, Chopra-Amiel-Gordon Syndrome, CAGS, ANKRD17
Interventions
Observational Study, Sample collection only
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Not applicable Interventional Results available

Utilizing Protein During Weight Loss to Impact Physical Function

NCT03074643
View directory record Official record
Conditions
Obesity, Weight Loss, Diet Modification, Aging, Weight Change, Body, Dietary Habits
Interventions
Weight loss intervention months 0-6, Exercise intervention months 0-6, Carbohydrate supplement for months 0-6, Protein supplement for months 0-6, Protein supplement for follow-up months 7-18
Behavioral · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 21, 2026, 2:36 PM EDT
Recruiting No phase listed Observational

Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure

NCT05711758
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity, Primary, Metabolic Disease, Delayed Gastric Emptying Following Procedure
Interventions
PSAM Treatment Patients
Procedure
Lead sponsor
Christopher C. Thompson, MD, MSc
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 21, 2026, 2:36 PM EDT
Withdrawn Not applicable Interventional

Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort

NCT01330589
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Placebo, St. Johns Wort
Drug
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 21, 2026, 2:36 PM EDT
Completed No phase listed Observational

Project TEACH: The Eating, Affect, and Cognitive Health Study

NCT04121598
View directory record Official record
Conditions
Pediatric Obesity, Binge Eating
Interventions
Observational
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
10 Years to 17 Years
Enrollment
48 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 21, 2026, 2:36 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

DNA Methylation and Vascular Function

NCT03527420
View directory record Official record
Conditions
Obesity, Vascular Dysfunction
Interventions
Exercise training
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Imaging Laterality in Chronic Stroke Patients

NCT03584425
View directory record Official record
Conditions
Stroke, Motor Cortex; Lesion
Interventions
Rasch modified version of the Fugl-Meyer Motor assessment, Anatomical image acquisition, Functional MRI task and acquisition
Diagnostic Test
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)

NCT04851873
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
OAV101
Genetic
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Up to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 2 Interventional Results available

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

NCT01604824
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 21, 2026, 2:36 PM EDT
Completed Phase 2 Interventional Results available

Reduced Carbohydrate Versus Fat in Obese Subjects

NCT00846040
View directory record Official record
Conditions
Obesity
Interventions
Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET
Other · Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 21, 2026, 2:36 PM EDT